"Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half. The study was funded by the National Eye Institu"...
FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION. Failure of improvement of keratitis following 7-10 days of administration of the drug suggests that the infection may be caused by a microorganism not susceptible to natamycin.
Continuation of therapy should be based on clinical re-evaluation and additional laboratory studies.
Adherence of the suspension to areas of epithelial ulceration or retention of the suspension in the fornices occurs regularly.
Use only if the container is undamaged.
Carcinogenesis, Mutagenesis, Impairment of Fertility: There have been no long term studies done using natamycin in animals to evaluate carcinogenesis, mutagenesis, or impairment of fertility.
Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with natamycin. It is also not known whether natamycin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. NATACYN® (natamycin ophthalmic suspension) 5% should be given to a pregnant woman only if clearly needed.
Nursing Mothers: It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when natamycin is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Last reviewed on RxList: 8/7/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Natacyn Information
Report Problems to the Food and Drug Administration
Get breaking medical news.